Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M.

Haematologica. 2019 Apr 11. pii: haematol.2018.203430. doi: 10.3324/haematol.2018.203430. [Epub ahead of print]

2.

Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway.

Němec V, Hylsová M, Maier L, Flegel J, Sievers S, Ziegler S, Schröder M, Berger BT, Chaikuad A, Valčíková B, Uldrijan S, Drápela S, Souček K, Waldmann H, Knapp S, Paruch K.

Angew Chem Int Ed Engl. 2019 Jan 21;58(4):1062-1066. doi: 10.1002/anie.201810312. Epub 2018 Dec 20.

PMID:
30569600
3.

Flow Cytometric Analysis of Nucleoside Transporters Activity in Chemoresistant Prostate Cancer Model.

Drápela S, Fedr R, Khirsariya P, Paruch K, Svoboda M, Souček K.

Klin Onkol. Spring 2018;31(Supplementum1):140-144.

PMID:
29808688
4.

Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.

Samadder P, Suchánková T, Hylse O, Khirsariya P, Nikulenkov F, Drápela S, Straková N, Vaňhara P, Vašíčková K, Kolářová H, Binó L, Bittová M, Ovesná P, Kollár P, Fedr R, Ešner M, Jaroš J, Hampl A, Krejčí L, Paruch K, Souček K.

Mol Cancer Ther. 2017 Sep;16(9):1831-1842. doi: 10.1158/1535-7163.MCT-17-0018. Epub 2017 Jun 15.

5.

Diastereoselective Flexible Synthesis of Carbocyclic C-Nucleosides.

Maier L, Khirsariya P, Hylse O, Adla SK, Černová L, Poljak M, Krajčovičová S, Weis E, Drápela S, Souček K, Paruch K.

J Org Chem. 2017 Apr 7;82(7):3382-3402. doi: 10.1021/acs.joc.6b02594. Epub 2017 Mar 20.

PMID:
28267331

Supplemental Content

Loading ...
Support Center